lascufloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, nalidixic acid derivatives | 5370 | 848416-07-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Lascufloxacin has strong antibacterial activity against the primary causative bacteria of community-acquired respiratory infections and also exhibits good activity against streptococci and anaerobic bacteria in the oral cavity, which have attracted attention recently as the causative bacterial of community-acquired pneumonia. Meanwhile, its penetration to the tissue of the lungs, ear, nose and throatis is good, and even at small doses, it maintains an effective drug concentration in infected tissue and demonstrates a high level of therapeutic effectiveness.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 75 | mg | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 22, 2019 | PMDA | Kyorin Pharmaceutical Co., Ltd. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01MA25 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peritonsillar abscess | indication | 15033003 | |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Pneumonia due to Mycoplasma pneumoniae | indication | 46970008 | |
| Bacterial laryngopharyngitis | indication | 55355000 | DOID:11195 |
| Pneumonia due to Klebsiella pneumoniae | indication | 64479007 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Abscess of lung | indication | 73452002 | DOID:0060317 |
| Peritonsillar cellulitis | indication | 102453009 | |
| Streptococcal infection of mouth | indication | 110267003 | |
| Acute Moraxella catarrhalis bronchitis | indication | 195722003 | |
| Legionella pneumonia | indication | 195889001 | |
| Acute bacterial bronchitis | indication | 233598009 | |
| Chronic bacterial respiratory infection | indication | 312117008 | |
| Bacterial upper respiratory infection | indication | 312118003 | |
| Bacterial lower respiratory infection | indication | 312119006 | |
| Pneumonia due to Staphylococcus aureus | indication | 441658007 | |
| Bacterial tonsillitis | indication | 703468005 | |
| Bacterial otitis media | indication | 703469002 | |
| Bacterial sinusitis | indication | 703470001 | |
| Pneumonia caused by Enterobacter | indication | 10311000175107 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.72 | acidic |
| pKa2 | 9.46 | Basic |
| pKa3 | 2.32 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D10772 | KEGG_DRUG |
| C000626327 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10823 | IUPHAR_LIGAND_ID |
| 1433857-09-0 | SECONDARY_CAS_RN |
| C4705101 | UMLSCUI |
| 10017 | INN_ID |
| 71528768 | PUBCHEM_CID |
| 55MOB566V7 | UNII |
Pharmaceutical products:
None